{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:24Z","timestamp":1786118964708,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/jcp.0b013e318184b4c5","type":"journal-article","created":{"date-parts":[[2008,9,12]],"date-time":"2008-09-12T07:01:02Z","timestamp":1221202862000},"page":"494-499","source":"Crossref","is-referenced-by-count":83,"title":["Insulin Resistance and Decreased Glucose-Stimulated Insulin Secretion After Acute Olanzapine Administration"],"prefix":"10.1097","volume":"28","author":[{"given":"Araba F.","family":"Chintoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve W.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony A.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose N.","family":"Nobrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adria","family":"Giacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1192\/bjp.187.6.537","article-title":"Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.","volume":"187","author":"Zipursky","year":"2005","journal-title":"Br J Psychiatry"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/01.yic.0000224786.75664.3b","article-title":"Early changes of plasma lipids during treatment with atypical antipsychotics.","volume":"21","author":"Rettenbacher","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-003-1529-4","article-title":"Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.","volume":"170","author":"Melkersson","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.","volume":"59","author":"Newcomer","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1176\/ajp.161.10.1837","article-title":"Randomized, controlled double-blind multicentre comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.","volume":"161","author":"Simpson","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":"Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.","volume":"62","author":"Henderson","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1345\/aph.1A157","article-title":"Olanzapine-induced diabetic ketoacidosis.","volume":"35","author":"Ragucci","year":"2001","journal-title":"Ann Pharmacother"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1046\/j.1464-5491.2000.00296.x","article-title":"Diabetes as a result of atypical anti-psychotic drugs-a report of three cases.","volume":"17","author":"Rigalleau","year":"2000","journal-title":"Diabet Med"},{"issue":"suppl 14","key":"R9-4-20210128","first-page":"1","article-title":"Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.","volume":"10","author":"Masand","year":"2005","journal-title":"CNS Spectr"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1067\/mpd.2001.114016","article-title":"Diabetic ketoacidosis associated with olanzapine in an adolescent patient.","volume":"138","author":"Selva","year":"2001","journal-title":"J Pediatr"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1034\/j.1600-0447.2002.2c257a.x","article-title":"Olanzapine-induced destabilization of diabetes in the absence of weight gain.","volume":"105","author":"Ramankutty","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis.","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy.","volume":"305","author":"Kapur","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","article-title":"Serotonin-dopamine interaction and its relevance to schizophrenia.","volume":"153","author":"Kapur","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0021-9258(19)77804-1","article-title":"Rates of glucose production and oxidation in normal and diabetic rats.","volume":"192","author":"Stetten","year":"1951","journal-title":"J Biol Chem"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2337\/diab.36.8.914","article-title":"Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates.","volume":"36","author":"Finegood","year":"1987","journal-title":"Diabetes"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2006.09.009","article-title":"Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain.","volume":"551","author":"Patil","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0924-977X(03)00072-5","article-title":"Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro.","volume":"4","author":"Melkersson","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2337\/diabetes.54.3.862","article-title":"Metabolic dysregulation with atypical antipsychotics occurs in absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs.","volume":"54","author":"Ader","year":"2005","journal-title":"Diabetes"},{"key":"R21-4-20210128","first-page":"854","article-title":"Effect of the atypical antipsychotic clozapine on insulin release in vitro.","volume":"28","author":"Melkersson","year":"2007","journal-title":"Neuro Endocrinol Lett"},{"issue":"suppl 1","key":"R22-4-20210128","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"suppl 7","key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S1098-3597(07)80019-6","article-title":"Metabolic consequences of hyperglycemia and insulin resistance.","volume":"8","author":"Jellinger","year":"2007","journal-title":"Clin Cornerstone"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/070674370404901106","article-title":"Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome.","volume":"49","author":"Cohn","year":"2004","journal-title":"Can J Psychiatry"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/oxfordjournals.schbul.a033504","article-title":"Prevalence and correlates of diabetes in national schizophrenia samples.","volume":"26","author":"Dixon","year":"2000","journal-title":"Schizophr Bull"},{"issue":"suppl 47","key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1192\/bjp.184.47.s76","article-title":"Metabolic disturbance in first-episode schizophrenia.","author":"Thakore","year":"2004","journal-title":"Br J Psychiatry"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/070674370605100608","article-title":"Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report.","volume":"51","author":"Cohn","year":"2006","journal-title":"Can J Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JCP.0b013e318184b4c5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:10:56Z","timestamp":1786036256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200810000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318184b4c5","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}